B. Metzler Seel. Sohn & Co. Ag Sarepta Therapeutics, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $9.53 Billion
- Q4 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 12,055 shares of SRPT stock, worth $886,524. This represents 0.02% of its overall portfolio holdings.
Number of Shares
12,055Holding current value
$886,524% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding SRPT
# of Institutions
535Shares Held
87.4MCall Options Held
1.55MPut Options Held
1.35M-
Black Rock Inc. New York, NY10.3MShares$759 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$668 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA8.7MShares$640 Million0.21% of portfolio
-
Janus Henderson Group PLC London, X04.33MShares$318 Million0.28% of portfolio
-
State Street Corp Boston, MA4.07MShares$299 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $6.44B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...